ArticleWorld journal of gastroenterology1998
A clinical evaluation of serum concentrations of intercellular adhesion molecule-1 in patients with gastric cancer.
Article in World journal of gastroenterology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
- Exploring the evolving function of soluble intercellular adhesion molecule-1 in junction dynamics during spermatogenesis.Frontiers in endocrinology · 2023Review
- Electrochemical sensing of blood proteins for mild traumatic brain injury (mTBI) diagnostics and prognostics: towards a point-of-care application.RSC advances · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the correlation between the serum soluble intercellular adhesion molecule-1 (sICAM-1) and the clinicopathologic features and to evaluate the possible prognostic significance of sICAM-1 concentration in gastric cancer.
methodsThirty-four patients with gastric cancer were prospectively included and evaluated. Venous blood samples were collected before the surgery. Sera were obtained by centrifugation, and store at -30 degree until assay. The control group consisted of 20 healthy volunteers. Serum concentrations of ICAM-1 were measured with the quantitative sandwich enzyme immunoassay technic. Differences between the two groups were analyzed by Student's t test. x+2s of normal control sICAM-1 was taken as upper limit to calculate the positive rates.
resultsThe mean value of serum ICAM-1 in patients with gastric cancer was 367.7&mgr;g/L plus minus 104.7&mgr;g/L and that of control group was 236.9&mgr;g/L plus minus 74.3&mgr;g/L, and the difference was significant (P < 0.001). The patients with tumor size of > = 5cm had significantly higher serum concentrations of sICAM-1 than those with smaller ones (406.7&mgr;g/L plus minus 90.2&mgr;g/L vs 319.9&mgr;g/L plus minus 105.3&mgr;g/L,P <0.01). Compared with stages I-II gastric cancer patients, patients with more advanced clinical stage (III-IIV) had higher levels of sICAM-1 (397.1&mgr;g/L plus minus 102.4&mgr;g/L vs 306.0&mgr;g/L plus minus 82.3&mgr;g/L,P <0.05).Difference was significant statistically in sICAM-1 levels between patients with positive lymph node status and those without lymph node involvement (403.6&mgr;g/L plus minus 99.7&mgr;g/L vs 302.7&mgr;g/L plus minus 81.4&mgr;g/L,P <0.01). No relation was observed between the level of sICAM-1 and grade of histological differentiation in the patients with gastric cancer.
conclusionSerum sICAM-1 concentration may be a valuable parameter for predicting the prognosis and degree of the gastric cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.